Literature DB >> 16396522

Polytherapy in bipolar disorder.

Daniel Lin1, Hiram Mok, Lakshmi N Yatham.   

Abstract

Bipolar disorder is a life-long condition that is associated with frequent recurrence/relapse of symptoms. Although putative mood stabilisers, such as lithium, are considered to improve the natural course of bipolar disorder, complete long-term remission is rarely achieved. In order to effectively control mood symptoms and to reduce relapse, clinicians often use polypharmacy to treat patients with bipolar disorder. In this article, we examine the recent literature on treatment strategies in bipolar disorder to determine if combination treatments provide additional benefit over monotherapy for the management of various phases of bipolar disorder. The evidence suggests that for acute mania a combination of lithium or valproate and an atypical antipsychotic is the most effective approach, with approximately 20% more patients responding to the combination than to monotherapy with any antimanic agent. Few studies have examined the use of combination therapy in comparison to monotherapy for bipolar depression. The limited evidence suggests that lithium plus an antidepressant appears to be more effective than lithium alone in those with lower serum lithium concentrations. Similarly, the combination of olanzapine plus fluoxetine is more effective than olanzapine alone. There is consensus that antidepressant monotherapy is not appropriate because of concerns of a manic switch, but monotherapy with lithium or lamotrigine may be adequate for mild to moderate bipolar depression. For maintenance treatment, commonly used agents, such as lithium, valproate or olanzapine appear to be most effective in preventing manic relapses, whereas lamotrigine is more effective in preventing depressive relapses. As a result of these findings, it makes intuitive sense to combine lamotrigine with lithium, valproate or an atypical antipsychotic to achieve better mood stability. However, the efficacy and safety of such combinations have not been systematically compared with monotherapy. Preliminary studies suggest that lithium plus valproate may be more effective than lithium alone in preventing affective relapses. Similarly, the combination of lithium or valproate plus olanzapine seems to be more effective than monotherapy with a mood stabiliser in preventing manic episodes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16396522     DOI: 10.2165/00023210-200620010-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  92 in total

1.  Risperidone in the treatment of acute mania: double-blind, placebo-controlled study.

Authors:  Sumant Khanna; Eduard Vieta; Benjamin Lyons; Fred Grossman; Mariëlle Eerdekens; Michelle Kramer
Journal:  Br J Psychiatry       Date:  2005-09       Impact factor: 9.319

2.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Authors:  M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-09

Review 3.  The foundations of effective management of bipolar disorder.

Authors:  V Kusumakar; L N Yatham; D R Haslam; S V Parikh; R Matte; V Sharma; P H Silverstone; S P Kutcher; S Kennedy
Journal:  Can J Psychiatry       Date:  1997-08       Impact factor: 4.356

Review 4.  Recent advances in treatment of acute mania.

Authors:  J C Chou
Journal:  J Clin Psychopharmacol       Date:  1991-02       Impact factor: 3.153

5.  Risperidone and paroxetine given singly and in combination for bipolar depression.

Authors:  Richard C Shelton; Stephen M Stahl
Journal:  J Clin Psychiatry       Date:  2004-12       Impact factor: 4.384

6.  Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.

Authors:  Gary S Sachs; Fred Grossman; S Nassir Ghaemi; Akiko Okamoto; Charles L Bowden
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

7.  A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission.

Authors:  Francesco Colom; Eduard Vieta; Anabel Martinez-Aran; Maria Reinares; Jose Manuel Goikolea; Antonio Benabarre; Carla Torrent; Merce Comes; Barbara Corbella; Gemma Parramon; Josep Corominas
Journal:  Arch Gen Psychiatry       Date:  2003-04

Review 8.  Suicidal behaviour in bipolar disorder: risk and prevention.

Authors:  Leonardo Tondo; Göran Isacsson; Ross Baldessarini
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 9.  Treatment of acute bipolar depression: a review of the literature.

Authors:  M Srisurapanont; L N Yatham; A P Zis
Journal:  Can J Psychiatry       Date:  1995-11       Impact factor: 4.356

10.  Divalproex sodium in the treatment of refractory affective disorders.

Authors:  M R Schaff; J Fawcett; J M Zajecka
Journal:  J Clin Psychiatry       Date:  1993-10       Impact factor: 4.384

View more
  27 in total

1.  Psychopharmacological treatment status in outpatients with bipolar disorder: a clinical survey in Germany.

Authors:  Arnim Quante; Sara Zeugmann; Francesca Regen; Annette Engelhardt; Ion-George Anghelescu
Journal:  Psychiatry Investig       Date:  2010-07-09       Impact factor: 2.505

2.  Managing bipolar disorder from urgent situations to maintenance therapy.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

3.  Time to rehospitalization in patients with bipolar I disorder on lithium or valproate with adjunctive antipsychotics.

Authors:  Ching-Hua Lin; Ching-Wen Huang; Cheng-Chung Chen; Yu-Fen Hsu; Wen-Ho Chang; Hsien-Yuan Lane
Journal:  Psychopharmacology (Berl)       Date:  2008-06-20       Impact factor: 4.530

4.  Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study.

Authors:  Stephanie Krüger; Rahul Sarkar; Ramona Pietsch; Dirk Hasenclever; Peter Bräunig
Journal:  Psychopharmacology (Berl)       Date:  2008-03-28       Impact factor: 4.530

5.  Lithium/Valproic acid combination and L-glutamate induce similar pattern of changes in the expression of miR-30a-5p in SH-SY5Y neuroblastoma cells.

Authors:  Nicoletta Croce; Sergio Bernardini; Carlo Caltagirone; Francesco Angelucci
Journal:  Neuromolecular Med       Date:  2014-08-23       Impact factor: 3.843

6.  Lithium chloride therapy fails to improve motor function in a transgenic mouse model of Machado-Joseph disease.

Authors:  Sara Duarte-Silva; Andreia Neves-Carvalho; Carina Soares-Cunha; Andreia Teixeira-Castro; Pedro Oliveira; Anabela Silva-Fernandes; Patrícia Maciel
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

Review 7.  Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder.

Authors:  Jose de Leon; Edoardo Spina
Journal:  Curr Psychiatry Rep       Date:  2018-03-12       Impact factor: 5.285

8.  The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms.

Authors:  Li-Kai Tsai; Yan Leng; Zhifei Wang; Peter Leeds; De-Maw Chuang
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

9.  Predictive factors for time to remission and recurrence in patients treated for acute mania: health outcomes of manic episodes (HOME) study.

Authors:  Kaan Kora; Mete Saylan; Cengiz Akkaya; Nesrin Karamustafalioglu; Nesrin Tomruk; Aziz Yasan; Timucin Oral
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

10.  A Canadian naturalistic study of a community-based cohort treated for bipolar disorder.

Authors:  Doron Sagman; Bobbie Lee; Ranjith Chandresena; Barry Jones; Elizabeth Brunner
Journal:  BMC Psychiatry       Date:  2010-03-19       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.